ASH 2022 | Updates from the HOPE-B trial: etranacogene dezaparvovec in adults with hemophilia B
In this video, Steven Pipe, MD, University of Michigan, Ann Arbor, MI, shares some updates from the Phase III HOPE-B trial, which is evaluating etranacogene dezaparvovec, an investigational gene therapy, in adult patients with severe or moderately severe hemophilia B (NCT03569891). In this study, patients with or without pre-existing AAV5 neutralizing antibodies received etranacogene dezaparvovec. Dr Pipe further discusses the results of this study, including factor IX activity, annualized bleed rate (ABR), and adverse events (AEs) observed. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sanofi: Consultancy; Sangamo Therapeutics: Consultancy; Takeda: Consultancy; CSL Behring: Consultancy; UniQure: Consultancy; Freeline: Consultancy; Novo Nordisk: Consultancy; Regeneron/Intellia: Consultancy; Siemens: Research Funding; Spark Therapeutics: Consultancy; BioMarin Pharmaceutical Inc.: Consultancy; HEMA Biologics: Consultancy; Apcintex: Consultancy; Pfizer: Consultancy; ASC Therapeutics: Consultancy; Roche/Genentech: Consultancy; Bayer: Consultancy; Yewsavin: Research Funding.
